World Congress on Pharmaceutical Biotechnology & Bioengineering March 25-26, 2019 Orlando, Florida, USA

Observing current trends, Big Data companies included in service provider segments are collaborating and entering into partnerships with healthcare providers, academic institutions, pharmaceuticals and biotechnology companies to support the growth of the PGx market and thus, service segment is anticipated to grow at a high CAGR of 16.22% from 2016 to 2022. Moreover, the Pharmaceutical segment will also gain from traction of the patients due to increasing awareness about the benefits of PGx solutions and adoption of these solutions in developing regions

Engineering Systems is a science that has played a major role the lives we live in the 21st century. In today’s technology driven world, engineering is the cornerstone and driver of innovation of the devices we utilize daily to improve our quality of life. The latter driver, namely the new ideas, is actually elements of research in engineering. This special section deals with the general topic of long term innovative topics for research in Chemical Engineering, Civilengineering, Electrical engineering, Mechanical engineering, Software engineering, Systems engineering and Interdisciplinary engineering. The peer-reviewed articles will showcase potentially high impact research topics or directions. The objective of this issue is to identify topics that are likely to result in a noteworthy impact on engineering industry in the next 25 to 50 years.

Modern pharmaceutical biotechnology encompasses gene cloning and recombinant DNA technology. The prime focus of the study was to know in depth of the concepts of Genetic engineering that are implemented in pharmaceutical industry. This study unleashes the paramount significance of Genetic engineering emerged out with outstanding success. Pharmaceutical trends are moving towards two profound technologies the first being Novel Drug Delivery system. This review work ensures the concepts of Recombinant rDNA, and the hybridoma techniques that are implemented in drug discovery and research. Genetic engineering now allows biological synthesis and large-scale production of several proteins with therapeutic potential. The principal challenge in this sphere is to identify new, medically and commercially significant targets. In the future, genetic engineering will surely provide invaluable tools for the study of the molecular basis of cellular control and pathophysiology, which will permit biochemists and medicinal chemists to design novel medicines.

From miniaturized home diagnostic instruments to therapeutic devices and to large scale hospital imaging and monitoring systems, healthcare is becoming increasingly dependent on technology. This course meets the growing need for biomedical and clinical engineers across the world by focusing on the design of medical devices from conception to application.

One of the few accredited courses of its kind in London, the program concentrates on the use of biomedical-driven engineering design and technology in healthcare settings so you can approach this multidisciplinary topic from the biological and medical perspective; the technological design and development perspective; and from the perspective of managing the organisation and maintenance of large scale equipment and IT systems in a hospital.

While its fragmented nature makes it difficult to quantify the overall biomedical engineering sector in terms of number of people employed and its worth, the global medical devices market alone is estimated to be worth US$381bn, according to medical market research company Kalorama.

With several medical conditions requiring extensive and continuous monitoring and early and accurate diagnosis becoming increasingly desirable, technology for biomedical applications is rapidly becoming one of the key ingredients of today and tomorrow’s medical care.

Diagnostic Test segment is holding the maximum market share and is expected to grow at 11.63% CAGR from 2016 to 2022. This is due to the increasing demand for diagnostic tests as patients are emphasizing more on pre-diagnosis treatments, increasing genetic disorders & mutational diseases, and government initiatives and investment in research and development programs among others. 

 

It is a fast-growing area of engineering and individuals would typically find themselves working in health services, the medical devices industry or research.

Scientists, researchers, and manufacturers in the medical and pharmaceutical sectors will continue to call upon biomedical engineers to address injuries and physical disabilities; to develop advanced prostheses and artificial body organs; and to improve healthcare technology and rehabilitation practices. As baby boomers live longer and remain active, there will be increased demand for biomedical devices and procedures, such as hip and knee replacements. 

When surveying the sector, it is also important to factor in the growing digital healthcare market. This is expected to be worth $233.3bn by 2020 (up from $60.8bn in 2013), with Asia-Pacific predicted as a key region.

The concept of BE has been accepted worldwide by the pharmaceutical industry and national regulatory authorities for over 20 years and is applied to new as well as generic products. As a result, thousands of high-quality generic drugs at reduced costs have become available in every corner of the globe. The assessment of BE is not a simple issue, however, and much of the research has been done in recent years to develop new and more effective approaches to the assessment of BE.

Since then, and after turn of the century, tremendous advancements have been made by the FDA and other regulatory authorities (national, international, and supranational), and by industry and academia in the area of assessment of bioequivalence. Currently approaches to determine BE of pharmaceutical products has been largely standardized. This has occurred due to discussion and consensus reached among various stakeholders at numerous national and international meetings, conferences, and workshops.

The pharmaceutical firms all over the world are burning the candle at both ends for attainment of market authorizations in various nations.

Bioethics can evaluate global justice by weighing human rights theory and future innovation at the macro level, and by addressing market forces and responsibilities at the micro level. Inherent structural features of pharmaceuticals, such as its reliance on research and development, cause the industry to employ pricing strategies that seem counter-intuitive to conventional wisdom, but that result in producing a just allocation as defined by market forces.

The Pharma industry is still assimilating the late 1990s wave of drug discovery technologies that are bringing about a powerful convergence of molecular biology, miniaturization, and materials and information technologies. Computer and chip technologies have given thousands of scientists the human genome as a bench tool, an opportunity unthinkable just 10 years ago. Scientists already have a publicly available catalog of 1.8 million single nucleotide polymorphisms to work with, and geometric expansion of proteomics research and technologies will create multiples of the existing data volume. The convergence of information technology and biology may well be the biggest story in biotechnology over the next decade. As we learn more about the cascades of reactions essential to disease and health, in silico modeling and testing will become more refined, perhaps alleviating some of the bottlenecks characteristic of wet biology.

The biotechnology era has experienced significant changes in the number of companies involved in vaccine manufacturing as well as in the production systems they use. Nevertheless, challenges in this area are multiple. In the current vaccine-manufacturing environment, time to market and cost effectiveness are key issues that need to be addressed in addition to smooth R&D and clinical studies. Furthermore, scale up and safety are important for maintaining a successful manufacturing process. As a result, state-of-the-art technologies to simplify vaccine development and manufacturing are becoming ever-more crucial

Vaccine development was discussed as important for global security at the World Economic Forum in Davos, Switzerland in January 2015. The first draft of the US House of Representatives “21st Century Cures” initiative includes actions to speed up vaccine approval and coverage. Proposals seek to tighten timelines for the Centers for Disease Control and Prevention (CDC) to recommend new vaccines, for FDA to expedite vaccine exports, and for the National Institutes of Health (NIH) to advance vaccine development. Researchers are looking for formulations that reduce cold-chain requirements, methods to boost process yield, and new approaches to document product quality.

With the advancement of human genome science now it will be easy for our clinicians to tailor the drug treatment through the specific prescription to the individual patient that target the drug to maximize its therapeutic efficacy and minimize the damage to surrounding healthy cells. The clinical trial studies can be adopted the advanced validated pharmacogenetic markers in order to increase the demonstration of therapeutic benefits without exposing non-receptive subjects. The clinical trial study can also be optimized as a small, fast and economic by undertaking pregenetic screening of those patients taking part in a clinical trial.

Global Pharmacogenomics Market Analysis: Focus on Ecosystem Players (Diagnostic Test, Pharmaceutical & Others), Therapeutic Applications (Oncology, Cardiovascular & Others)

The global Pharmacogenomics market is expected to grow over $14.85 billion by 2022. Rapid advancement and innovation of new healthcare technologies such as next generation sequencing, High Throughput Screening, and Digital Polymerase Chain Reaction are developing a strong base for the growth of Pharmacogenomics market

The application of nanobiotechnology has far ranging uses within a number of sectors of the life sciences industry, including drug discovery, formulation, clinical assessment, drug delivery and monitoring. The reasons for the increase in value was said to be multifaceted, relating to developments in cancer and viral treatments consolidation in the pharmaceutical industry and the expiration of patents. Pressure on companies to prolong the lifecycle of existing drugs and also to produce new products is a driver behind the increased use of biopharmaceutical nanotechnology

A decade of success in expressing a variety of proteins in livestock has brought three human recombinant proteins to human clinical trials. Recent progress has drawn on molecular biology and reproductive physiology to improve the efficiency of producing and reproducing useful transgenic founder animals, and to improve the expression of heterologous proteins.

The market growth has been the driving force on efforts for the development of new therapeutic proteins, in which transgenesis emerges as key component. The use of the transgenic animal platform offers attractive possibilities, residing on the low production costs allied to high productivity and quality of the recombinant proteins

The approval of two mammary gland-derived recombinant proteins for commercial and clinical use has boosted the interest for more efficient, safer and economic ways to generate transgenic founders to meet the increasing demand for biomedical proteins worldwide.

The incredible amount of recent biologic therapeutic discoveries has led to an increased need for scientific and engineering knowledge available to characterize and bio manufacture these large and complex molecules. Today’s biologic manufacturing facilities incorporate analytical and process development capabilities to develop and test the scale-up of the process to deliver sufficient productivity of a quality product.

There are various regulatory opinions in the United States, European, Japanese pharmaceutical industries, and other countries that regulate biologics.

Over the past two decades there has been a decisive shift towards large molecule, biological drugs or biopharmaceuticals, and away from traditional chemically synthesised, small molecule drugs Revenue from biopharmaceuticals in 2016 was in the range of $280-300 billion and is forecasted to grow at about 10% for the foreseeable future. One particular biomolecule dominates though in biopharmaceuticals currently and that is the monoclonal antibody.

The number approved for use as biopharmaceuticals has steadily increased and in 2016 accounted for five of the top ten selling drugs globally with revenues of $46 billion

This appetite for monoclonal drugs shows no sign of abating with this article on the therapeutic monoclonal antibody market anticipating 2020 revenues of $125 billion. A recent FiercePharma report also predicted that by 2022 monoclonal antibodies will make up 60% of the top selling cancer drugs.

A biologic therapeutic product, also known as a biologic, is a therapeutic product developed to treat a variety of diseases. This biologic product can be a monoclonal antibody, a vaccine, a tissue, or various proteins such as cytokines, enzymes, fusion proteins, whole cells, and viral and nonviral gene therapies

The global biotechnology market is expected to reach USD 727.1 billion by 2025, according to a new report by Grand View Research, Inc. The emergence of certain key themes in the biotechnology market is expected to drive growth in this industry to a lucrative extent.

These key themes include regenerative medicine and genetics in diagnostics. The companies focusing on the development of regenerative therapies is anticipated to drive sector growth through to 2025. Technological advancements pertaining to the penetration of artificial intelligence in this industry is expected to fuel progress with potential avenues. The companies are engaged in unleashing machine learning in order to understand individual cancer cases, while recommending clinical trials.

Supportive government (and its allied agencies) policies related to synthetic biology is a major growth impacting driver in this sector. Developed economies such as UK and the U.S. are critically monitoring and funding synthetic biology R&D initiatives. For example, in 2010, a six months’ review of synthetic biology headed by a panel of expert scientists was enforced by the U.S. President and subsequently conducted a hearing of the Energy and Commerce Committee exclusively concerning synthetic biology.